Default company panoramic image
Otracelogofinalsmall

OTraces, Inc.

Simple Screening Blood Test Assays for Cancers; Breast, Ovarian, Prostate, Colon, Lung, and Melanoma.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Rockville, MD, USA
  • Currency USD
  • Founded September 2008
  • Employees 5
  • Incorporation Type C-corp
  • Website otraces.com

Company Summary

OTraces has blood based diagnostic detection methods for cancer that have superior predictive power, 90% for Prostate Cancer. We have data for breast, prostate, ovarian and lung all with greater than 95% predictive power. The system is fully automated for the clinical lab and in production. OTraces Active Surveillance test for low grade prostate cancer transition to aggressive is ready for final validation and market launch.

Team

  • Default avatar
    Richard Saul Ph.D.
    VP Product Deleopemnt

    In-depth experience in the research, development of diagnostic products in clinical chemistry and rapid microbiology; Founder of Axo Diagnostics; Vice President of Product Development at Celsis-Lumac; Director of Assay Development at IGEN; Director – Chemistry R&D, Dade Stratus; Experience in both large and startup organizations, in management and lab level, in assay and systems development for unit-dose devices and high throughput instruments.

  • Default avatar
    Keith Lingenfelter
    CEO, Founder, Member of BOD

    VP Diagnostics at IGEN; developed a breakthrough luminescent immunoassay technology for measuring proteins and DNA in biological fluids, Licensed to Roche, Eisai Inc., Akzo Pharma and ABI/Perkin Elmer, Positioned IGEN for an IPO and sale to Roche for $1.5 billion in 2005.
    Prior to IGEN, at Abbott Laboratories; strategic marketing and management of large R&D programs that developed chemistry instrumentation and reagents for diagnostic market.

  • Default avatar
    Alain Cappeluti
    CFO, Founder, Member of BOD

    More than 30 years experience in finance and public accounting for private and public companies; has participated directly in $4 billion of corporate financing; Management in biotech industry includes BioReliance, Human Genome Sciences, and CoGenesys. Joined HGS in 1992 at its founding and served as VP of Finance; Part of the team that spun Cogenesys out from HGS in 2006 and was its’ CFO until it was sold to Teva Pharma in 2008 for $400 M

  • F48ff2d6 5273 4468 aee6 8c0ae0e6c2f4
    CEO, Founder, Member of BOD

    VP Diagnostics at IGEN; developed a breakthrough luminescent immunoassay technology for measuring proteins and DNA in biological fluids, Licensed to Roche, Eisai Inc., Akzo Pharma and ABI/Perkin Elmer, Positioned IGEN for an IPO and sale to Roche for $1.5 billion in 2005.
    Prior to IGEN, at Abbott Laboratories; strategic marketing and management of large R&D programs that developed chemistry instrumentation and reagents for diagnostic market.

Previous Investors

  • Default avatar
    State of Virginia|Former CFO Human Genome Sciences.|Other Angels
    Unconfirmed